FDA OKs Vaccine Therapy for Prostate Cancer

The Food and Drug Administration approved the first therapeutic vaccine for prostate cancer today, after a three years of evaluations with the vaccine's manufacturers and researchers. Earlier clinical trials of the vaccine, called Provenge, showed that the therapy could extend life by four to five months in men with advanced prostate cancer. But in 2007, the FDA asked for more research since studies curiously showed that Provenge seemed to extend life without slowing the progression of cancer....Full Story
Commenting on this article is closed.